The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

Irinotecan, a standard of care therapy for CRC, elicits cytotoxic effects by generating double strand breaks resulting in DNA damage. The activation of the ATM pathway plays a fundamental role in regulating the cellular response and repair to DNA damage. The objective of this preclinical study was t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Greene, Justin, Nguyen, Anna, Bagby, Stacey M., Jones, Gemma N., Tai, WM., Quackenbush, Kevin S., Schreiber, Anna, Messersmith, Wells A., Devaraj, Kalpana M., Blatchford, Patrick, Eckhardt, S. Gail, Cadogan, Elaine B., Hughes, Gareth D., Smith, Aaron, Pitts, Todd M., Arcaroli, John J.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762293/
https://ncbi.nlm.nih.gov/pubmed/29340025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22920
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires